|
🐜
|
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
100 auth.
E. McDonald,
Antoine de Weck,
M. Schlabach,
E. Billy,
Konstantinos J. Mavrakis,
G. Hoffman,
Dhiren Belur,
D. Castelletti,
Elizabeth Frias,
Kalyani Gampa,
J. Golji,
Iris Kao,
Li Li,
P. Megel,
Thomas A. Perkins,
...
N. Ramadan,
D. Ruddy,
S. Silver,
S. Sovath,
M. Stump,
Odile Weber,
R. Widmer,
Jianjun Yu,
Kristine Yu,
Yingzi Yue,
D. Abramowski,
Elizabeth Ackley,
R. Barrett,
Joel E. Berger,
J. Bernard,
Rebecca Billig,
S. Brachmann,
F. Buxton,
R. Caothien,
J. Caushi,
Franklin Chung,
Marta Cortés-Cros,
Rosalie S. deBeaumont,
Clara Delaunay,
Aurore Desplat,
William Duong,
Donald A. Dwoske,
Richard Eldridge,
Ali Farsidjani,
Fei Feng,
Jiajia Feng,
D. Flemming,
W. Forrester,
G. Galli,
Zhenhai Gao,
François Gauter,
V. Gibaja,
K. Haas,
M. Hattenberger,
T. Hood,
Kristen E. Hurov,
Zainab Jagani,
M. Jenal,
Jennifer A. Johnson,
Michael D. Jones,
A. Kapoor,
Joshua M. Korn,
Jilin Liu,
Qiumei Liu,
Shumei Liu,
Yue Liu,
Alice T. Loo,
Kaitlin J Macchi,
Typhaine Martin,
Gregory McAllister,
Amandine Meyer,
S. Mollé,
R. Pagliarini,
Tanushree Phadke,
Brian Repko,
Tanja Schouwey,
F. Shanahan,
Qiong Shen,
C. Stamm,
C. Stephan,
V. Stucke,
R. Tiedt,
Malini Varadarajan,
K. Venkatesan,
Alberto C. Vitari,
M. Wallroth,
J. Weiler,
Jing Zhang,
C. Mickanin,
V. Myer,
J. A. Porter,
A. Lai,
H. Bitter,
E. Lees,
N. Keen,
A. Kauffmann,
F. Stegmeier,
F. Hofmann,
Tobias Schmelzle,
W. Sellers
|
9 |
2017 |
9
🐜
|
|
🐜
|
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
21 auth.
Heather A. Huet,
J. Growney,
Jennifer A. Johnson,
Jing Li,
S. Bilic,
L. Ostrom,
M. Zafari,
C. Kowal,
Guizhi Yang,
Axelle Royo,
...
M. Jensen,
B. Dombrecht,
Kris Meerschaert,
J. Kolkman,
K. Cromie,
R. Mosher,
Hui Gao,
A. Schuller,
R. Isaacs,
W. Sellers,
S. Ettenberg
|
6 |
2014 |
6
🐜
|
|
🐜
|
LBY135, a novel anti‐DR5 agonistic antibody induces tumor cell–specific cytotoxic activity in human colon tumor cell lines and xenografts
17 auth.
Jing Li,
D. Knee,
Youzhen Wang,
Qingxiu Zhang,
Jennifer A. Johnson,
Jane Cheng,
Helen He,
Christine Miller,
Zhifang Li,
C. Kowal,
...
J. Eckman,
Betty Tang,
Jing Yuan,
Liqing Chen,
Q. Deveraux,
M. Nasoff,
D. Stover
|
4 |
2008 |
4
🐜
|
|
🐜
|
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages
21 auth.
Anupama Reddy,
J. Growney,
Nick Wilson,
Caroline M. Emery,
Jennifer A. Johnson,
Rebecca Ward,
Kelli-Ann Monaco,
Joshua M. Korn,
J. Monahan,
M. Stump,
...
F. Mapa,
Christopher J. Wilson,
Janine L. Steiger,
J. Ledell,
R. Rickles,
V. Myer,
S. Ettenberg,
R. Schlegel,
W. Sellers,
Heather A. Huet,
J. Lehár
|
3 |
2015 |
3
🐜
|
|
🐜
|
Abstract 3853: TAS266, a novel tetrameric nanobody agonist targeting death receptor 5 (DR5), elicits superior antitumor efficacy than conventional DR5-targeted approaches
18 auth.
Heather A. Huet,
A. Schuller,
Jing Li,
Jennifer A. Johnson,
B. Dombrecht,
Kris Meerschaert,
K. Cromie,
S. Bilic,
Sharon Li,
A. Garner,
...
Sandra L. Nunes,
R. Chopra,
K. Clark,
Megan Yao,
S. Fawell,
D. Stover,
W. Sellers,
S. Ettenberg
|
3 |
2012 |
3
🐜
|
|
🐜
|
Tumor-cell specific cytotoxic activity of LBY135, a novel anti- DR5 agonistic antibody
7 auth.
Jing Li,
Qingxiu Zhang,
Jennifer A. Johnson,
D. Knee,
Q. Deveraux,
M. Nasoff,
...
D. Stover
|
2 |
2007 |
2
🐜
|
|
🐜
|
732 First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21–1480, an affinity-balanced PD-L1x4–1BBxHSA trispecific antibody: results of phase 1 dose escalation
14 auth.
J. Luke,
Melissa Johnson,
S. Gadgeel,
A. Spira,
James Yang,
Jennifer A. Johnson,
T. Losch-Beridon,
D. Snell,
S. Warmuth,
Maureen Cleaver,
...
E. Baur,
David Urech,
P. Lichtlen,
David S. Hong
|
1 |
2022 |
1
🐜
|
|
🐜
|
Bioactive and / or Targeted dendriimikonjugaatteja
16 auth.
D. Tomalia,
J. Baker,
A. Bielinska,
R. Cheng,
M. Fazio,
D. Hedstrand,
Jennifer A. Johnson,
D. A. Kaplan,
S. Klakamp,
J. W. J. Kruper,
...
J. Kukowska-Latallo,
Bartely D Maxon,
L. Piehler,
I. Tomlinson,
L. Wilson,
R. Yin
|
0 |
1995 |
0
🐜
|
|
🐬
|
Abstract #3716: Preclinical toxicology comparing intermittent and continuous administration of PX-866, a novel irreversible phosphoinositide-3-kinase (PI-3K) inhibitor
J. Millard,
L. Pestano,
Jennifer A. Johnson,
Kirk Dl
|
0 |
2009 |
0
🐬
|
